Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial

Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was significantly superior to tamoxifen in terms of efficacy and safety in the adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) earl...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mansel, R, Locker, G, Fallowfield, L, Benedict, Á, Jones, D
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2007
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360294/
https://ncbi.nlm.nih.gov/pubmed/17622238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603804
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky